Search Results - "Siner, Joshua I"
-
1
Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype
Published in Blood (23-05-2013)“…Recombinant canine B-domain deleted (BDD) factor VIII (FVIII) is predominantly expressed as a single-chain protein and exhibits greater stability after…”
Get full text
Journal Article -
2
Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model
Published in Human gene therapy (01-07-2011)“…Intravascular delivery of adeno-associated virus (AAV) vector is commonly used for liver-directed gene therapy. In humans, the high prevalence of neutralizing…”
Get more information
Journal Article -
3
AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice
Published in Blood (05-03-2015)“…Emerging successful clinical data on gene therapy using adeno-associated viral (AAV) vector for hemophilia B (HB) showed that the risk of cellular immune…”
Get full text
Journal Article -
4
Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models
Published in JCI insight (06-10-2016)“…Processing by the proprotein convertase furin is believed to be critical for the biological activity of multiple proteins involved in hemostasis, including…”
Get full text
Journal Article -
5
AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life
Published in Molecular therapy. Methods & clinical development (14-03-2024)“…The hemophilias are the most common severe inherited bleeding disorders and are caused by deficiency of clotting factor (F) VIII (hemophilia A) or FIX…”
Get full text
Journal Article -
6
Human Factor VIII Variants with Diminished PACE-Furin Cleavage Exhibit Increased Biological Activity and Therapeutic Efficacy
Published in Blood (06-12-2014)“…During intracellular processing, factor VIII (FVIII) undergoes proteolysis at multiple sites with the most predominant cleavage at a Paired basic Amino acid…”
Get full text
Journal Article -
7
Unexpected Role of PACE/Furin Cleavage Site in FVIII Biology: Implications for Hemophilia a Therapy
Published in Blood (06-12-2014)“…The paired basic amino acid cleaving enzyme (PACE)/Furin is a protein convertase system that plays a vital role in several biological processes, including…”
Get full text
Journal Article -
8
Bioengineering Factor VIII B-Domain Sequences Improves Function and Efficacy in Hemophilia A Models
Published in Blood (16-11-2012)“…Abstract 2208 We previously reported that recombinant canine B-domain deleted factor VIII (FVIII) was expressed predominantly (>75%) as a single-chain protein…”
Get full text
Journal Article -
9
Tolerance Induction To FIX Padua With AAV Liver Gene Transfer In Inhibitor-Prone Hemophilia B Dogs
Published in Blood (15-11-2013)“…Emerging data from early phase clinical studies of AAV gene therapy for hemophilia B (HB) (factor IX [FIX] deficiency) show sustained expression of therapeutic…”
Get full text
Journal Article -
10
Insights Into the Mechanism of Zymogen Protein C Protection Against Cancer Progression
Published in Blood (16-11-2012)“…Abstract 3350 Cancer is frequently associated with activation of coagulation, and a procoagulant state facilitates tumor metastasis. Recent studies have…”
Get full text
Journal Article